Zentalis Pharmaceuticals, Inc. ZNTL
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) is an oncology drug developer. Its lead program, Azenosertib (ZN-c3), is in Phase 3 for Cyclin E1-positive platinum-resistant ovarian cancer. Its next catalyst on record is Azenosertib: DENALI Part 2 topline readout (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Azenosertib — DENALI Part 2 topline readout (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Azenosertib (ASPENOVA, confirmatory) | Cyclin E1+ PROC | small molecule | — |
| Azenosertib (DENALI Part 2, registrational) | Cyclin E1+ PROC | small molecule | DENALI Part 2 topline 2027-H1 |
| Azenosertib + chemo/bevacizumab (MUIR) | Ovarian cancer | small molecule | — |
Recent results and decisions
- Aug 6, 2026completed enrollment Enrollment completed in DENALI Parts 2a and 2b; Part 2c still enrolling.
Enrollment in DENALI Parts 2a and 2b is complete.
Filing - May 5, 2026started First patient dosed in the Phase 3 ASPENOVA trial of azenosertib vs chemotherapy (about 420 patients, primary endpoint PFS).
today announced that the first patient has been dosed in the Phase 3 ASPENOVA clinical trial
Filing - Apr 9, 2026positive Prespecified DENALI Part 2a interim analysis showed a clearly differentiated response rate for 400mg QD 5:2 over 300mg, with comparable safety; 400mg selected as pivotal dose (no ORR figures given).
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groups
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.